ʻO nā nīnau e nīnau pinepine ʻia e pili ana iā Sunitinib Malate 丨 AASraw
Hana ʻo AASraw i ka paukū Cannabidiol (CBD) a me ka Hemp Essential Oil i ka nui!

Sunitinib Malate

 

  1. Nāʻike o Sunitinib Malate
  2. He aha ka mea e hiki ai iā mākou ke hoʻohana iā Sunitinib Malate?
  3. Pehea e hana ai ʻo Sunitinib Malate?
  4. Pehea e lawe ai iā Sunitinib Malate?
  5. Pehea e mālama ai iā Sunitinib Malate?
  6. Pehea mākou e ʻike ai i nā hopena ʻaoʻao o Sunitinib Malate?
  7. He aha nā lāʻau ʻē aʻe e hoʻopili iā Sunitinib Malate?
  8. Ua ʻae ʻo FDA iā Sunitinib Malate e like me ka hoʻomaʻamaʻa Adjuvant o ka Carcinoma Renal Cell
  9. Ma hea e hiki ai iaʻu ke kūʻai aku iā Sunitinib Malate Online?

 

Sunitinib Malate (CAS:341031-54-7) i ʻike ʻia ma SUGEN, kahi hui biotechnology kahi i paionia i nā mea hoʻopā kinase protein. ʻO ia ke kolu o ka papa o nā hui pū me SU5416 a me SU6668. ʻO ka manaʻo o kahi mimic ATP e hoʻokūkū ai me ATP no ka hoʻopaʻa ʻana i ka pūnaewele catalytic o nā receptor tyrosine kinases. ʻO kēia kumumanaʻo i alakaʻi ʻia i ka mea hou o ka nui o nā mea liʻiliʻi liʻiliʻi liʻiliʻi mole mole mole, e like me Gleevec, Sutent, Tarceva a me nā mea ʻē aʻe he nui.

 

Nāʻike o Sunitinib Malate

ʻO Sunitinib Malate kahi melemele i ka ʻalani. ʻO Sunitinib Malate kahi mole-mole liʻiliʻi i māka nui ʻia mea hoʻokipa tyrosine kinase (RTK) mea kāohi. Ma Ianuali 26, 2006, ua ʻae ʻae ʻia ka agena e ka US FDA no nā hōʻailona o ka mālama ʻana i ka carcinoma puʻupaʻa puʻupaʻa (RCC) a me ka tumatinib-resistive gastrointestinal stromal tumor (GIST). No kēia mau kumuhana, loaʻa maʻamau ʻo Sunitinib Malate ma ke ʻano he hana i haʻi waha ʻia. Ua pāpā ʻo Sunitinib Malate i ka hōʻailona pūnaewele pūnaewele e ka ʻimi ʻana i nā nui RTK. Hoʻopili kēia i nā mea loaʻa i ka platelet (PDGF-R) a me nā mea loaʻa ulu ulu endothelial (VEGF-R). Hoʻopau pū ʻo Sunitinib Malate iā KIT (CD117), ka RTK e hoʻokele i ka hapa nui o GIST. Hoʻohui, Sunitinib Malate pāpā i nā RTK ʻē aʻe me RET, CSF-1R, a me flt3.

 

He aha ka mea e hiki ai iā mākou ke hoʻohana iā Sunitinib Malate? 

Hoʻohana ʻia ʻo Sunitinib Malate e mālama i nā mākua me ka maʻi ʻaʻai ʻōpala i hohola ʻole (localized) a me ka poʻe i makaʻu nui i ka hoʻi hou ʻana o RCC ma hope o ka ʻoki ʻana o ka hakuʻala.

Hoʻohana ʻia ʻo Sunitinib Malate e mālama i ke kanesa maʻi kōkō holomua (carenaloma cell renal advanced a i ʻole RCC).

Hoʻohana ʻia ʻo Sunitinib Malate e mālama i kahi maʻi ʻaʻai laha ʻole o ka ʻōpū, ʻōpū, a i ʻole esophagus i kapa ʻia ʻōpū stromal gastrointestinal (GIST) a ke lawe ʻoe i ka lāʻau imatinib mesylate a ʻaʻole ia i hoʻokū i ka maʻi ʻaʻai mai ka ulu ʻana a i ʻole hiki ʻole iā ʻoe ke lawe i ka imatinib mesylate. ʻO Gleevec kahi inoa inoa inoa inoa o Novartis Pharmaceuticals Corporation.

Hoʻohana ʻia ʻo Sunitinib Malate e mālama i kekahi ʻano maʻi ʻaʻai pancreatic i ʻike ʻia e like me nā tumreatic neuroendocrine tumors (pNET) i holomua a ʻaʻole hiki ke mālama ʻia me ke ʻoki kino.

 

Pehea e hana ai ʻo Sunitinib Malate?

ʻO Sunitinib Malate kahi mea pāpā liʻiliʻi i ka nui o nā receptor tyrosine kinases, kekahi o ia mau mea i hoʻopili ʻia i ka ulu ulu ʻana, angiogenesis pathologic, a me ka holomua metastatic o ka maʻi ʻaʻai. Hoʻoikaika ka ʻākena i nā mea loaʻa ulu ulu i loaʻa i ka platelet - (PDGFRα a me PDGFRβ), nā mea ulu ulu endothelial vascular (VEGFR1, VEGFR2, a me VEGFR3), receptor cell cell factor (KIT), FMS-like tyrosine kinase 3, kolone-stimulate factor receptor ʻano 1, a me ka laina glial cell-laina i loaʻa mai i ka neurotrophic factor receptor (RET). Ua hōʻike ʻia ka pāpā ʻana ʻo Sunitinib Malate i ka hana a me ka hana o kēia mau receptor tyrosine kinases i nā hoʻokolohua biochemical a me nā cellular a me nā hoʻowalewale hoʻowalewale pūnaewele. Hōʻike ka metabolite mua o Sunitinib Malate i ka ikaika e like me ka mākua hui i nā hoʻokolohua biochemical a me nā kelepona.

Ua kāohi ʻo Sunitinib Malate i ka phosphorylation o nā receptor tyrosine kinases (PDGFRβ, VEGFR2, KIT) i loko o nā tumen xenografts e hōʻike ana i nā pahuhopu kinetona tyrosine kinase i loko o vivo a kāohi i ka ulu ulu a me nā metastasis i kekahi mau mana hoʻokolohua. Hoʻomaʻa ka ʻākena i ka ulu ʻana o nā hunaola tumele e hōʻike ana i ka disregulated target receptor tyrosine kinases (PDGFR, RET, a i ʻole KIT) i vitro a me PDGFRβ-a me VEGFR2-tumo tumi angiogenesis i loko o vivo.

 

Sunitinib Malate

 

Pehea e lawe ai iā Sunitinib Malate?

ʻO ka Sunitinib Malate kauka a kāu kauka e kuhikuhi ai e hilinaʻi ʻia i nā kumu he nui. Pākuʻi ʻia kēia mau mea:

❶ ke ʻano a me ke koʻikoʻi o ke ʻano āu e hoʻohana nei iā Sunitinib Malate e mālama ai

❷ nā kūlana olakino ʻē aʻe āu

❸ nā lāʻau ʻē aʻe āu e lawe nei

E kauoha kauka loa i kāu kauka liʻiliʻi e hāʻawi i ka hopena i makemake ʻia.

Hōʻike ka ʻikepili aʻe i nā lāʻau i hoʻohana pinepine ʻia a koi ʻia paha. Eia nō naʻe, e mālama pono i nā lāʻau a ke kauka i kuhikuhi ai nāu. E hoʻoholo kāu kauka i ka mea ʻoi loa e kūpono i kāu mau pono.

 

♦ Nā ʻano lāʻau a me nā ikaika

Hele mai ʻo Sunitinib Malate ma ke ʻano he capsule āu e ale ai. Loaʻa ia i kēia mau ikaika: 12.5 milligrams (mg), 25 mg, 37.5 mg, a me 50 mg.

 

♦ Ka hana no ka maʻi ʻaʻai gastrointestinal

ʻO ka maʻa maʻamau o Sunitinib Malate no nā ʻōpū stromal gastrointestinal (GISTs) he 50 mg hoʻokahi i kēlā me kēia lā no 4 mau pule. Hahai ʻia e 2 pule me ka ʻole o ka lāʻau. A laila, e hana hou ʻoe i ke pōʻaiapuni.

E hoʻomau paha ʻoe i ka lawe ʻana iā Sunitinib Malate a hiki i ka maʻi ʻana o kou maʻi ʻaʻai a i ʻole ʻaʻole hiki i kou kino ke ʻae i ka mālama ʻana me ka lāʻau. E hoʻoholo kāu kauka i ka manawa hea ʻoe e haʻalele ai i ka lawe ʻana iā Sunitinib Malate. No nā kikoʻī e pili ana i ka hoʻohana ʻia ʻana o Sunitinib Malate e mālama ai iā GIST, e ʻike i ka loulou ma lalo.

 

♦ Ka hana no ke kanesa maʻi ʻaʻai

Hoʻohana pū ʻia ʻo Sunitinib Malate e mālama i kahi ʻano maʻi ʻaʻai kolo i kapa ʻia ʻo carcinoma cell renal advanced (RCC). ʻO ka maʻa maʻamau o Sunitinib Malate no RCC kiʻekiʻe he 50 mg i kēlā me kēia lā no 4 mau pule. Hahai ʻia e 2 pule me ka ʻole o ka lāʻau. A laila, e hana hou ʻoe i ke pōʻaiapuni.

E hoʻomau paha ʻoe i ka lawe ʻana iā Sunitinib Malate a hiki i ka maʻi ʻana o kou maʻi ʻaʻai a i ʻole ʻaʻole hiki i kou kino ke ʻae i ka mālama ʻana me ka lāʻau. E hoʻoholo kāu kauka i ka manawa hea ʻoe e haʻalele ai i ka lawe ʻana iā Sunitinib Malate. No ka ʻike hou aku e pili ana i ka hoʻohana ʻia ʻana o Sunitinib Malate e mālama ai i ka RCC holomua, e ʻike i ka loulou ma lalo.

 

♦ Ka hana no ka hoʻomaʻamaʻa adjuvant o ke kanesa maʻi ʻaʻai

Hoʻohana pū ʻia ʻo Sunitinib Malate ma ke ʻano he lāʻau lapaʻau kōkua no kekahi ʻano maʻi ʻaʻai puʻuwai i kapa ʻia ʻo RCC ma hope o kahi nephrectomy (ka wehe ʻoki ʻana o kahi puʻupaʻa). ʻO ka maʻamau ana o Sunitinib Malate no kēia hoʻohana he 50 mg hoʻokahi i kēlā me kēia lā no 4 mau pule. Hahai ʻia e 2 pule me ka ʻole o ka lāʻau. E hana hou ʻoe i kēia pōʻai a ʻeiwa mau manawa. No nā kikoʻī e pili ana i ka hoʻohana ʻia ʻana o Sunitinib Malate ma ke ʻano he lāʻau lapaʻau kōkua no RCC, e ʻike i ka loulou ma lalo.

 

♦ Ka hana no ka maʻi ʻaʻai pancreatic

ʻO ka maʻa maʻamau o Sunitinib Malate no nā kūpuna neuroendocrine pancreatic holomua (pNETs) he 37.5 mg i kēlā me kēia lā.

E hoʻomau paha ʻoe i ka lawe ʻana iā Sunitinib Malate a hiki i ka maʻi ʻana o kou maʻi ʻaʻai a i ʻole ʻaʻole hiki i kou kino ke ʻae i ka mālama ʻana me ka lāʻau. E hoʻoholo kāu kauka i ka manawa hea ʻoe e haʻalele ai i ka lawe ʻana iā Sunitinib Malate.

 

ʻIke ʻia: he kuhikuhi wale nō ke ana, e ʻoluʻolu e kōkua i ka nānā ʻana i nā kikoʻī e kēia pūnaewele:www.fda.gov .

 

ʻO AASraw ka mea hana ʻoihana ʻo Sunitinib Malate.

E ʻoluʻolu e kaomi ma aneʻi no ka ʻike ʻōlelo. Hana iā mākou

 

Pehea e mālama ai iā Sunitinib Malate?

E mālama i kēia lāʻau i loko o ka pahu i komo mai i loko, ua paʻa a paʻa, a mai kahi hikiʻole o nā keiki. E kūʻai iā ia i ke ana wela a ma kahi'ē aʻe mai ka wela a me ka meaʻoihana (ʻaʻole i loko o ka lumi lepo).

He mea nui ka mālamaʻana i nā lāʻau a pau mai kaʻikeʻana a hiki i nā keiki e like me nā pahu (e like me nā pilina o ka pule hebedoma a me ka mea no nā maka o ka maka, ka'ōpū, nā pāpale, a me nā mea inu)ʻaʻole hiki ke kū'ē i ka'ōpiopio a hiki i nā keiki'ōpiopio ke wehe iā lākou. No ka paleʻana i nā keiki liʻiliʻi mai ka lāʻauʻawaʻawa, e hoʻopaʻa mau i nā piko palekana a kau koke i ka lāʻau i kahi wahi palekana - kahi eʻoi aku ana i waho a ma waho aku o ko lākou mau maka a hiki.

Pono e hoʻolei ʻia nā lāʻau i koi ʻole ʻia i nā ala kūikawā e hōʻoia i ka hiki ʻole i nā holoholona, ​​nā keiki, a me nā poʻe ʻē aʻe ke hoʻopau iā lākou. Eia nō naʻe, ʻaʻole pono ʻoe e kaomi i kēia lāʻau i ka lua. Akā, ʻo ke ala ʻoi loa e hoʻolilo i kāu lāʻau i loko o kahi papahana hoʻihoʻi lāʻau. E kamaʻilio me kāu kauka lāʻau a kāhea paha i kāu ʻōpala a me nā hana hoʻopōʻaiapuni kūloko e aʻo e pili ana i nā papahana hoʻihoʻi i kou kaiāulu. E ʻike i ka hoʻolei palekana ʻana o ka FDA Pūnaewele lapaʻau no ka ʻike hou aku inā ʻaʻole ʻoe e komo i kahi papahana hoʻihoʻi.

 

Pehea mākou e ʻike ai i nā hopena ʻaoʻao o Sunitinib Malate?

ʻO Sunitinib Malate nā hopena maikaʻi ʻole i manaʻo ʻia he hiki ke mālama ʻia a me nā hanana o nā hanana kūiki koʻikoʻi haʻahaʻa.

ʻO nā hanana maikaʻi ʻole e pili pū ana me Sunitinib Malate therapy ka māluhiluhi, ka maʻi palahēhē, ka paupō, anorexia, hypertension, kahi ʻili melemele, ka ʻili a ka wāwae wawae lima, a me ka gastratitis. pinepine me Sunitinib Malate ma mua o ka placebo i loaʻa i ka diarrhea, anorexia, ka hoʻoliʻiliʻi o ka ʻili, mucositis / stomatitis, astenia, ka ʻono i hoʻololi ʻia, a me ka constipation. Koi ʻia nā hoʻoliʻiliʻi hana ma 50% o nā maʻi i hoʻopaʻa ʻia i ka RCC i mea e mālama ai i nā mea ʻona nui o kēia agena.

Kūpilikiʻi (papa 3 a 4 paha) nā hanana maikaʻi ʻole ma ≤10% o nā mea maʻi a komo pū me ke kiʻekiʻe kiʻekiʻe, ka luhi, ka astenia, ka maʻi diarrhea, a me ka chemotherapy-induced acral erythema. ʻO nā hana ʻino ʻole e pili pū ana me Sunitinib Malate therapy me lipase, amylase, neutrophils, lymphocytes, a me nā platelet. ʻO ka hypothyroidism a me ka erythrocytosis hiki ke hoʻohuli ʻia e pili pū me Sunitinib Malate. Hiki ke mālama ʻia ka hapa nui o nā hanana maikaʻi ʻole ma o ke kākoʻo kākoʻo, hoʻokiʻoki ʻana o ka lāʻau, a i ʻole ka hōʻemi ʻana o ka lāʻau.

ʻO kahi noiʻi i hana ʻia ma MD Anderson Cancer Center i hoʻohālikelike ʻia i nā hopena o nā mea maʻi maʻi maʻi metastatic renal cell i loaʻa iā Sunitinib Malate ma ka papa hana maʻamau (50 mg / 4 mau pule ma kahi o 2 mau pule) me ka poʻe i loaʻa iā Sunitinib Malate me nā lā nui pinepine pinepine a pōkole hoʻi. (papa kuhikuhi ʻokoʻa). Ua ʻike ʻia ʻo ke ola holoʻokoʻa, ke ola manuahi o ka holomua a me ka mālama ʻana i ka lāʻau i ʻoi aku ka kiʻekiʻe ma nā mea maʻi i loaʻa iā Sunitinib Malate ma ka manawa koho ʻē aʻe. Ua loaʻa i nā mea maʻi ka hoʻomanawanui maikaʻi a me ka haʻahaʻa o nā hanana pōpilikia e alakaʻi pinepine ai i ka hoʻopau ʻana i ka mālama ʻana i nā mea maʻi maʻi maʻi maʻi metastatic.

 

Sunitinib Malate

 

He aha nā lāʻau ʻē aʻe e hoʻopili iā Sunitinib Malate?

Hiki i ka Sunitinib Malate ke hana i kahi pilikia puʻuwai koʻikoʻi. Hiki ke kiʻekiʻe aʻe kou makaʻu inā ʻoe e hoʻohana i nā lāʻau ʻē aʻe no nā maʻi, ka hānō, nā pilikia puʻuwai, ke koko kiʻekiʻe, ke kaumaha, nā maʻi noʻonoʻo, ka maʻi ʻaʻai, ka malaria, a me ka HIV.

I kekahi manawa ʻaʻole palekana ka hoʻohana ʻana i kekahi mau lāʻau i ka manawa like. Hiki i kekahi mau lāʻau ke hoʻololi i kou kiʻekiʻe o ke koko o nā lāʻau ʻē aʻe āu e lawe ai, kahi e hoʻonui ai i nā hopena a i ʻole e hoʻemi pono ai ka lāʻau. E haʻi i kāu kauka e pili ana i kāu mau lāʻau ʻē aʻe āpau, ʻo ia hoʻi: ka lāʻau osteoporosis.

ʻAʻole piha kēia papa inoa. Hiki i nā lāʻau ʻē aʻe ke hoʻopili iā Sunitinib Malate, e like me nā lāʻau i kuhikuhi ʻia a me nā lāʻau lapaʻau, nā huaora, a me nā huahana lāʻau. ʻAʻole pau nā launa lāʻau hiki ʻole i helu ʻia ma aneʻi.

 

Ua ʻae ʻo FDA iā Sunitinib Malate ma ke ʻano he Adjuvant lapaʻau o ka maʻi puʻuwai puʻupaʻa

Ma Nowemapa 16, 2017, ua ʻae ka Food and Drug Administration Sunitinib Malate (Sunitinib Malate, Pfizer Inc.) no ka hoʻomaʻamaʻa olakino ʻana o nā mea maʻi makua i ka makaʻu nui o ka carcinoma pūnana renal hou ma hope o nephrectomy.

Hoʻokumu ʻia ka ʻae ma ke kikowaena waena, kūwaho hoʻi, makapō makapō, pālua ʻia, hoʻokolokolo (S-TRAC), i nā maʻi he 615 me ka makaʻu nui o ka hoʻi hou ʻana o ka RCC ma hope o ka nephrectomy. Hoʻohui ʻia nā mea maʻi ma 1: 1 e loaʻa iā 50 mg Sunitinib Malate hoʻokahi manawa i kēlā me kēia lā, 4 mau pule ma ka hoʻomaʻamaʻa a ukali ʻia e 2 mau pule, a i ʻole kahi placebo. ʻO ke ola me ka maʻi ʻole Median no nā mea maʻi e lawe ana iā Sunitinib Malate he 6.8 makahiki (95% CI: 5.8, ʻaʻole i hiki) hoʻohālikelike ʻia me 5.6 makahiki (95% CI: 3.8, 6.6) no nā mea maʻi e loaʻa ana ka placebo (HR = 0.76; 95% CI: 0.59 , 0.98; p = 0.03). I ka manawa o ka anamanaʻo DFS, ʻaʻole makua nā ʻike ola āpau.

ʻO nā hopena maikaʻi loa (≥25%) iā Sunitinib Malate ka luhi / astenia, diarrhea, mucositis / stomatitis, nausea, hoʻemi i ka makemake / anorexia, ka luaʻi, ʻeha o ka ʻōpū, ka maʻi wāwae wāwae, hypertension, nā hanana kahe ʻana, ke kahe o ka dysgeusia / hoʻololi , dyspepsia, a me thrombositopenia. Aia i loko o ka lepili kahi ʻōlelo aʻoaʻo i pahu ʻia e makaʻala i nā poʻe ʻoihana olakino a me nā mea maʻi e pili ana i ka makaʻu o ka hepatoxicity, a ʻo ka hopena e hopena i ka hopena o ke ake a make paha.

ʻO ka lāʻau i koi ʻia o Sunitinib Malate no ka hoʻomaʻamaʻa adjuvant o RCC he 50 mg waha waha hoʻokahi i kēlā me kēia lā, me ka ʻole a me ka ʻole o ka ʻai, 4 mau pule ma ka hoʻomaʻamaʻa a ukali ʻia e 2 mau hebedoma no ʻeiwa mau pule he 6 mau pule.

 

ʻIke ʻia Loaʻa nā ʻike piha i ke kuhikuhi ma:accessdata.fda.gov  PDF 

 

Ma hea e hiki ai iaʻu ke kūʻai aku iā Sunitinib Malate Online? 

Nui a nui nā mea hoʻolako / mea hana o Sunitinib Malate ka pauka i ka mākeke, ke ʻike nei he mea nui ka mea nui no nā poʻe āpau e pono koke i kēia huahana. Ke hoʻoholo mākou e kūʻai i ka pauka Sunitinib Malate i ka mākeke, pono mākou e aʻo hou e pili ana i ia mea, ʻike pehea e hoʻohana ai a ʻo ia ke ʻano o ka hana, nā pilikia ke lawe mākou i Sunitinib Malate pauma…. Eia hou, ʻo ke kumukūʻai a me ka maikaʻi e lilo i kā mākou hopohopo ma mua o ka kūʻai ʻana.

Ma hope o kā mākou nānā ʻana i nā ʻikepili mai ka mākeke, hoʻohālikelike ʻia i nā mea hoʻolako, nānā maikaʻi ʻo AASraw no nā poʻe e makemake e kūʻai i ka nui. Sunitinib Malate pauka, kāohi ʻia kā lākou hana ma lalo o ke kūlana cGMP, hiki ke nānā i ke ʻano i kēlā me kēia manawa a hāʻawi paha lākou i nā hōʻike hoʻāʻo a pau ke kauoha ʻoe. No ka Sunitinib Malate paukū kumukūʻai / kumukūʻai, pono ia e kūpono, i koʻu mau maka. Ma muli o ka loaʻa ʻana o nā kumukūʻai he nui mai nā mea kūʻai mai Sunitinib Malate ʻokoʻa, ke hoʻohālikelike ʻia me ka maikaʻi, manaʻo wau ʻaʻole maikaʻi ʻole ka aasraw.

ʻO AASraw ka mea hana ʻoihana ʻo Sunitinib Malate.

E ʻoluʻolu e kaomi ma aneʻi no ka ʻike ʻōlelo. Hana iā mākou

 

Reference

[1] ʻOihana Hoʻokōʻai Meaʻai. Sunitinib (Sutent) Ke kuhikuhi nei i ka ʻike. 2015.

[2] CA Naranjo, U. Busto, a me EM Sellers, "ʻO kahi hana no ka koho ʻana i ka likelike o nā hopena lāʻau hōʻino," Clinical Pharmacology and Therapeutics, vol. 30, ʻaʻole. 2, pp. 239-245, 1981.

[3] Z. Ansari a me MK George, "Hoʻokomo ʻia ka lāʻau thrombositopenia i waena o ka sunitinib i kahi mea maʻi me ka carcinoma pūnana renal metastatic: kahi hōʻike hihia," Journal of Medical Case Reports, vol. 7, ʻatikala 54, 2013.

[4] K. Sakai, K. Komai, D. Yanase, a me M. Yamada, "Plasma VEGF ma ke ʻano he marker no ka hōʻoia a me ka mālama ʻana i ka neuropathy vasculitic," Ka Nupepa o Neurology, Neurosurgery a me Psychiatry, vol. 76, ʻaʻole. 2, ʻatikala 296, 2005.

[5] ʻOihana Lapaʻau ʻEulopa. Sunitinib (SUTENT). Hōʻuluʻulu Manaʻo o nā Huahana Huahana. 2015.

[6] Pajares B, Torres E, Trigo JM et al. Nā mea kāohi ʻo Tyrosine kinase a me nā launa lāʻau: kahi loiloi me nā ʻōlelo kūpono. ʻO Clin Transl Oncol 2012; 14: 94-101.

[7] ʻO Teo YL, Ho HK, ʻo Chan A. Metabolism e pili ana i nā lāʻau lapaʻau lāʻau e pili ana i ka lāʻau lapaʻau me nā mea kāohi tyrosine kinase: ka hoʻomaopopo ʻana i kēia manawa, nā pilikia a me nā ʻōlelo aʻoaʻo. ʻO Br J Clin Pharmacol 2015; 79: 241-253.

[8] Jamie Dlugosch (2009-03-13). "E hoʻopakele nā ​​meaolaola a me Sutent iā Pfizer?". Hale Kukui

[9] BMJ 31-Jan-2009 "NICE a me ka pilikia o nā lāʻau ʻaʻai" p271

[10] Blay JY, Reichardt P (Iune 2009). "ʻO ka tumom gastromestinal stromal tumom maʻEulopa: kahi loiloi o nā ʻōlelo hoʻomaikaʻi hoʻomaikaʻi hou". ʻO ka loea Rev Anticancer Ther. 9 (6): 831–8. hana: 10.1586 / era.09.34. PMID 19496720. S2CID 23601578.

0 Likes
1543 Views

E hiki no hoi i like

Comments ua paa.